Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Zymeworks Inc (NQ: ZYME ) 11.51 +0.12 (+1.05%) Streaming Delayed Price Updated: 12:39 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 100,747 Open 11.50 Bid (Size) 11.49 (3) Ask (Size) 11.52 (3) Prev. Close 11.39 Today's Range 11.35 - 11.58 52wk Range 6.015 - 13.14 Shares Outstanding 57,771,204 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Zymeworks Announces Participation in Upcoming Investor Conferences August 22, 2024 From Zymeworks Inc. Via GlobeNewswire Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock August 01, 2024 Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024 From Zymeworks Inc. Via GlobeNewswire Performance YTD +10.89% +10.89% 1 Month +7.07% +7.07% 3 Month +32.15% +32.15% 6 Month -6.95% -6.95% 1 Year +53.67% +53.67% More News Read More Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results August 01, 2024 From Zymeworks Inc. Via GlobeNewswire Navigating 6 Analyst Ratings For Zymeworks June 06, 2024 Via Benzinga Zymeworks Announces Participation in Upcoming Investor Conferences July 30, 2024 From Zymeworks Inc. Via GlobeNewswire Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer July 25, 2024 From Zymeworks Inc. Via GlobeNewswire Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate July 22, 2024 From Zymeworks Inc. Via GlobeNewswire Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024 July 11, 2024 From Zymeworks Inc. Via GlobeNewswire Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers June 17, 2024 From Zymeworks Inc. Via GlobeNewswire Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare June 15, 2024 Via Talk Markets Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer June 10, 2024 From Zymeworks Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
